Larry Goldstein to Triglycerides
This is a "connection" page, showing publications Larry Goldstein has written about Triglycerides.
Connection Strength
0.338
-
Extended-release niacin therapy and risk of ischemic stroke in patients with cardiovascular disease: the Atherothrombosis Intervention in Metabolic Syndrome with low HDL/High Triglycerides: Impact on Global Health Outcome (AIM-HIGH) trial. Stroke. 2013 Oct; 44(10):2688-93.
Score: 0.110
-
Baseline blood pressure, low- and high-density lipoproteins, and triglycerides and the risk of vascular events in the Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) trial. Atherosclerosis. 2009 Jun; 204(2):515-20.
Score: 0.078
-
Relative effects of statin therapy on stroke and cardiovascular events in men and women: secondary analysis of the Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) Study. Stroke. 2008 Sep; 39(9):2444-8.
Score: 0.077
-
Atherogenic dyslipidemia and residual cardiovascular risk in statin-treated patients. Stroke. 2014 May; 45(5):1429-36.
Score: 0.029
-
Risk of stroke and cardiovascular events after ischemic stroke or transient ischemic attack in patients with type 2 diabetes or metabolic syndrome: secondary analysis of the Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) trial. Arch Neurol. 2011 Oct; 68(10):1245-51.
Score: 0.024
-
Relative and cumulative effects of lipid and blood pressure control in the Stroke Prevention by Aggressive Reduction in Cholesterol Levels trial. Stroke. 2009 Jul; 40(7):2486-92.
Score: 0.021